Skip to search formSkip to main contentSkip to account menu

RRM1 gene

Known as: Ribonucleotide Reductase M1 Gene, RIBONUCLEOTIDE REDUCTASE, LARGE SUBUNIT, RIBONUCLEOTIDE REDUCTASE, M1 SUBUNIT 
This gene plays a role in the inhibition of cell migration, invasion, and metastasis.
National Institutes of Health

Related topics

Related topics

6 relations
Cell ProliferationDNA ReplicationImmunologic Deficiency SyndromesNucleotide Metabolism

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
The study investigated the clinical significance of RRM1 (ribonucleoside reductase subunit M1), TUBB3 (tubulin-β-III), TOP2A (DNA… 
2014
2014
Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy
The aim of this study was to examine the prognostic value of breast cancer susceptibility gene 1 (BRCA1), excision repair cross… 
2013
2013
mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
BACKGROUND To explore mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 genes in tumor tissue of… 
2012
2012
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer
PurposeTo comparatively evaluate the prognostic or predictive value of ribonucleotide reductase M1 (RRM1) and excision repair… 
2012
2012
Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells
Gemcitabine is a deoxycytidine analog used for the treatment of a wide range of solid tumors. Its efficacy is however often… 
2012
2012
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma
Objective Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of… 
2011
2011
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C
Aim:  Controversy exists over the optimal dosing for the nucleoside analogue gemcitabine. A pharmacological advantage is achieved… 
2010
2010
Histology- and gender-related associations of ERCC1, RRM1, and TS biomarkers in 1,802 patients with NSCLC: Implications for therapy.
7513 Background: Histology-based decision making for non-small cell lung cancer (NSCLC) has recently been advocated. We… 
2009
2009
Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer.
Highly Cited
2008
Highly Cited
2008
Efficacy of Gemcitabine in Patients with Non–Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene
Purpose: High ribonucleotide reductase M1 (RRM1) expression in resected lung cancers has been associated with better clinical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)